Deep Apple Therapeutics, Inc. — Form D
Deep Apple Therapeutics, Inc. of NEW YORK, NY, a company, filed a Form D exempt-offering notice with the SEC on 2021-12-22. The offering totals $52.0M, of which $5.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2021-12-22
- Form: D
- Accession: 0001901003-21-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $52.0M
- Amount sold: $5.0M
- Remaining: $47.0M
- Investors: 1
- Date of first sale: 2021-12-06
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-426368
Issuer
- Name: Deep Apple Therapeutics, Inc.
- CIK: 0001901003
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2021
- Address: 230 PARK AVENUE, SUITE 2800, NEW YORK, NY, 10169
- Phone: 857-352-3657
Officers, directors & promoters (6)
| Name | Role | Location |
|---|
| Paul Da Silva Jardine | Director | New York, NY |
| Michael Ehlers | Director | Morristown, NJ |
| Seth Harrison | Director | Redwood City, CA |
| Spiros Liras | Director | New York, NY |
| Brian Shoichet | Director | New York, NY |
| Spiros Liras | Executive Officer | New York, NY |
More